ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 580,03
-0,69%
Dow Jones
40 799,04
1,46%
DAX
18 518,03
-0,44%
Brent Oil
83,39
-1,13%
Bitcoin
64 510,45
-0,53%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Teva Pharmaceutical Industries Ltd (TEVA)

  7. Teva Pharmaceutical Industries Ltd (TEVA) Actualités

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
05/05/201720h00Business WireTeva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary EndpointNYSE:TEVATeva Pharmaceutical Industries Ltd
05/05/201715h31Edgar (US Regulatory)Report of Foreign Issuer (6-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
05/05/201714h00Business WireTeva Announces Publication of COPAXONE® (glatiramer acetate injection) Pregnancy Data in the International Journal of MS CareNYSE:TEVATeva Pharmaceutical Industries Ltd
03/05/201705h27Dow Jones NewsPerrigo Says Investigators Searched Its Offices in Generic-Drug ProbeNYSE:TEVATeva Pharmaceutical Industries Ltd
27/04/201714h00Business WireTeva Announces Publication of ARM-TD Study Results in Neurology® for the Investigational Use of Deutetrabenazine in Tardive ...NYSE:TEVATeva Pharmaceutical Industries Ltd
26/04/201722h09Business WireTeva Announces Launch of Generic Vytorin® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
26/04/201715h02Business WireTeva Announces Planned Departure of Eyal Desheh, Group Executive Vice President and Chief Financial OfficerNYSE:TEVATeva Pharmaceutical Industries Ltd
20/04/201714h42Business WireTeva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and SalmeterolNYSE:TEVATeva Pharmaceutical Industries Ltd
19/04/201714h00Business WireTeva Showcases CNS Portfolio at 69th Annual Meeting of the American Academy of NeurologyNYSE:TEVATeva Pharmaceutical Industries Ltd
06/04/201714h30Business WireTeva to Report First Quarter 2017 Financial Results on May 11, 2017NYSE:TEVATeva Pharmaceutical Industries Ltd
03/04/201714h32Business WireTeva erzielt positives Ergebnis für Etikett von dreimal wöchentlichem COPAXONE® 40 mg/ml in EuropaNYSE:TEVATeva Pharmaceutical Industries Ltd
03/04/201713h08Business WireTeva obtient une issue positive pour l’étiquetage de COPAXONE® 40 mg/ml 3 fois par semaine en EuropeNYSE:TEVATeva Pharmaceutical Industries Ltd
03/04/201708h00Business WireTeva Receives Positive Outcome for COPAXONE® 40 mg/ml 3 Times Weekly Label in EuropeNYSE:TEVATeva Pharmaceutical Industries Ltd
16/03/201718h58Business WireTeva Announces Launch of Authorized Generic of Minastrin® 24 Fe (norethindrone acetate & ethinyl estradiol tablets & ferrous...NYSE:TEVATeva Pharmaceutical Industries Ltd
13/03/201716h00Business WireTeva to Present at the Barclays Global Annual Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
06/03/201716h56Business WireTeva to Present at the Cowen & Company 37th Annual Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
01/03/201716h56Business WireTeva Announces Launch of Generic Pristiq® in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
28/02/201714h00Business WireTeva Announces Priority Review Granted by FDA for SD-809 for Treatment of Tardive DyskinesiaNYSE:TEVATeva Pharmaceutical Industries Ltd
16/02/201700h10Business WireTeva Files 2016 Annual Report on Form 20-FNYSE:TEVATeva Pharmaceutical Industries Ltd
15/02/201723h32Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NYSE:TEVATeva Pharmaceutical Industries Ltd
14/02/201718h11Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NYSE:TEVATeva Pharmaceutical Industries Ltd
14/02/201709h02Dow Jones NewsTeva Posts Loss on a Write-Down -- WSJNYSE:TEVATeva Pharmaceutical Industries Ltd
13/02/201715h13Dow Jones NewsAllergan to Buy Fat Treatment Maker Zeltiq for $2.3 BillionNYSE:TEVATeva Pharmaceutical Industries Ltd
13/02/201712h42Business WireTeva Reports Full Year and Fourth Quarter 2016 Financial ResultsNYSE:TEVATeva Pharmaceutical Industries Ltd
08/02/201722h59PR Newswire (US)Bernstein Liebhard LLP Investigates Claims On Behalf Of Shareholders Of Teva Pharmaceuticals Industries, Ltd.NYSE:TEVATeva Pharmaceutical Industries Ltd
08/02/201717h39Dow Jones NewsAllergan Results Boosted by New, Established Drugs -- UpdateNYSE:TEVATeva Pharmaceutical Industries Ltd
08/02/201717h00Dow Jones NewsAllergan Results Boosted by New, Established DrugsNYSE:TEVATeva Pharmaceutical Industries Ltd
06/02/201722h53Business WireTeva Appoints Dr. Yitzhak Peterburg as Interim Chief Executive Officer, Succeeding Erez VigodmanNYSE:TEVATeva Pharmaceutical Industries Ltd
02/02/201714h00Business WireTeva Confirms Generic Victoza® Patent Challenge in the United StatesNYSE:TEVATeva Pharmaceutical Industries Ltd
01/02/201721h01Business WireTeva to Report Fourth Quarter 2016 Financial Results on February 13, 2017NYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA

Dernières Valeurs Consultées

EU
PX4
SBF 120
EU
SGO
Cie de SaintGobain
EU
ORA
Orange
NASDAQ
AAPL
Apple
EU
GLE
Societe Generale
NASDAQ
NVDA
NVIDIA
EU
BN
Danone
COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
EU
VK
Vallourec
SPI
SP500
S&P 500
EU
LR
Legrand
EU
BEL20
Bel 20
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés